ArticleScientific reports2025
Characterization of transmitted drug resistance among recently infected HIV-1 men who have sex with men in Hebei Province, China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pretreatment drug resistance profiles and transmission dynamics of HIV-1 among adults aged ≥50 in Hebei Province, China.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Despite transmitted drug resistance (TDR) surveillance is the critical role in HIV-1 prevention strategies, epidemiological data remain scarce for newly infected men who have sex with men (MSM) in Hebei Province, China. To address this data gap, we conducted a cross-sectional study involving 173 MSM recently infected with HIV-1. Plasma samples were subjected to HIV-1 RNA extraction, followed by amplification and sequencing of the pol gene region (PR-RT: 1.3 kb; IN: 0.8 kb). In this study, 173 sequences were successfully sequenced, and the sequencing success rate was 92.5% (173/187). Subtyping analysis revealed a predominance of CRF07_BC (36.4%, 63/173) and CRF01_AE (32.3%, 56/173), with a notable proportion of unique recombinant form (URF, 20.2%, 35/173). The overall TDR prevalence was 7.51% (13/173), categorized by drug class as follows: protease inhibitors (PIs, 2.31%, 4/173), nucleoside reverse transcriptase inhibitors (NRTIs, 1.16%, 2/173), non-nucleoside reverse transcriptase inhibitors (NNRTIs, 2.31%, 4/173), and integrase strand transfer inhibitors (INSTIs, 2.89%, 5/173). Notably, one participant exhibited concurrent resistance to NRTIs, NNRTIs, and INSTIs. While these findings suggest moderate TDR control in Hebei's MSM population, we emphasize the necessity for sustained surveillance to dynamically assess treatment program efficacy, optimize second-line therapy regime, and guide public health interventions. This study provides the first comprehensive TDR profile for recently infected individuals in Hebei, offering critical insights for regional HIV-1 management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.